I Love Lund (LOVE) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
6 Jun, 2025Executive summary
Focus on local investments in innovative Lund-based companies, with a diversified portfolio across sectors and a strong emphasis on sustainability and community engagement.
Q1 2025 marked by a negative result, mainly due to a one-time accounting change and selective write-downs, not operational underperformance.
New investments in Avidicare AB and a convertible loan in Alixlabs AB; fewer but larger transactions this quarter.
High shareholder engagement, with a record turnout at the annual meeting and new board member Mats Lind.
Financial highlights
Net sales: SEK 0 (unchanged year-over-year); other operating income SEK 6,975 (13,950).
Operating income: SEK -751,000 (Q1 2024: -686,000).
Net result after financial items: SEK -4.2 million (Q1 2024: -2.0 million), mainly due to SEK -2.9 million one-off from valuation change.
Earnings per share: SEK -9.83 (Q1 2024: -5.28).
Equity per share: SEK 83.16 (Q1 2024: 109.2); NAV per share: SEK 104.39.
Solidity: 98.6%.
Cash at period end: SEK 1.46 million.
Outlook and guidance
A major investment in a local life science company is imminent post-period.
No formal forecasts provided.
Latest events from I Love Lund
- Full-year net result improved to SEK -4.8m, with a diversified, innovation-focused portfolio.LOVE
Q4 202523 Jan 2026 - Stable operating loss, improved net result, and strong equity amid active portfolio management.LOVE
Q3 202524 Oct 2025 - NAV and book value rose in Q2, driven by portfolio gains and new investment in Lead Biologics.LOVE
Q2 202525 Jul 2025 - Net loss driven by write-downs, but strong equity and new capital raised for future investments.LOVE
Q3 202413 Jun 2025 - Improved results and increased investments mark a cautiously optimistic first half of 2024.LOVE
Q2 202413 Jun 2025 - Losses increased on write-downs, but solvency and liquidity remain robust.LOVE
Q4 20246 Jun 2025